Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma

Journal of Computer Assisted Tomography

Volumn 32, Issue 3, 2008, Pages 379-385

  Kim, Suk Jung ^a,b   Kim, Seung Hoon ^a,e   Lee, Jongmee ^c   Chang, Samuel ^a   Kim, Young Sun ^a   Kim, Seong Hyun ^a   Jeon, Yong Hwan ^d   Choi, Dongil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Kangwon National University College of Medicine   (South Korea)

^e Samsung Medical Center   (South Korea)

Author keywords

Hepatocellular carcinoma; Liver; Liver CT; Liver MR

Indexed keywords

DIAGNOSIS; IMAGE SEGMENTATION; MULTIDETECTOR COMPUTED TOMOGRAPHY;

DIAGNOSTIC PERFORMANCE; HEPATOCELLULAR CARCINOMA; HIGH SENSITIVITY; LIVER CT; LIVER MAGNETIC RESONANCE; MEAN VALUES; MULTIDETECTOR ROW COMPUTED TOMOGRAPHY; PARALLEL IMAGING TECHNIQUES; RECEIVER OPERATING CHARACTERISTIC CURVES; RECEIVER OPERATING CHARACTERISTICS ANALYSIS;

MAGNETIC RESONANCE IMAGING;

FERUCARBOTRAN; IOPAMIDOL; CONTRAST MEDIUM; IRON; OXIDE; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER LOBECTOMY; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONTRAINDICATION; LIVER TUMOR; METHODOLOGY;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; HUMANS; IRON; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; OXIDES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 45849148865     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e3180de5c80     Document Type: Article

References (31)

1. Frayne R, Goodyear BG, Dickhoff P, et al. Magnetic resonance imaging at 3.0 Tesla: challenges and advantages in clinical neurological imaging. Invest Radiol. 2003;38:385-402.
2. Kim YK, Kwak HS, Kim CS, et al. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology. 2006;238:531-541.
3. Kim SH, Choi D, Kim SH, et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2005;184:1069-1076.
4. Kang BK, Lim JH, Kim SH, et al. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology. 2003;226:79-85.
5. Lee JM, Kim IH, Kwak HS, et al. Detection of small hypervascular hepatocellular carcinomas in cirrhotic patients: comparison of superparamagnetic iron oxide-enhanced MR imaging with dual-phase spiral CT. Korean J Radiol. 2003;4:1-8.
6. Choi D, Kim S, Lim J, et al. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus combined helical CT during arterial portography and CT hepatic arteriography. AJR Am J Roentgenol. 2001;176:475-482.
7. Bluemke DA, Paulson EK, Choti MA, et al. Detection of hepatic lesions in candidates for surgery: comparison of ferumoxides-enhanced MR imaging and dual-phase helical CT. AJR Am J Roentgenol. 2000;175:1653-1658.
8. Bartolozzi C, Donati F, Cioni D, et al. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol. 2004;14:14-20.
9. Reimer P, Rummeny EJ, Daldrup HE, et al. Clinical results with Resovist: a phase 2 clinical trial. Radiology. 1995;195:489-496.
10. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol. 1989; 152:167-173.
11. Saini S, Stark DD, Hahn PF, et al. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology. 1987;162:217-222.
12. Chang JM, Lee JM, Lee MW, et al. Superparamagnetic iron oxide-enhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Invest Radiol. 2006;41:168-174.
13. Pattany PM. 3T MR imaging: the pros and cons. AJNR Am J Neuroradiol. 2004;25:1455-1456.
14. Takahashi M, Uematsu H, Hatabu H. MR imaging at high magnetic fields. Eur J Radiol. 2003;46:45-52.
15. Ba-Ssalamah A, Nobauer-Huhmann IM, Pinker K, et al. Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases. Invest Radiol. 2003;38:415-422.
16. Norris DG. High field human imaging. J Magn Reson Imaging. 2003;18:519-529.
17. Uematsu H, Takahashi M, Dougherty L, et al. High field body MR imaging: preliminary experiences. Clin Imaging. 2004;28:159-162.
18. Willinek WA, Born M, Simon B, et al. Time-of-flight MR angiography: comparison of 3.0-T imaging and 1.5-T imaging - initial experience. Radiology. 2003;229:913-920.
19. Ludeke KM, Roschmann P, Tischler R. Susceptibility artefacts in NMR imaging. Magn Reson Imaging. 1985;3:329-343.
20. Kurihara Y, Yakushiji YK, Tani I, et al. Coil sensitivity encoding in MR imaging: advantages and disadvantages in clinical practice. AJR Am J Roentgenol. 2002;178:1087-1091.
21. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology. 2005;42:27-34.
22. Fleiss JL. The measurement of interrater agreement. In: Fleiss JL, ed. Statistical Methods for Rates and Proportions, 2nd ed. New York, NY: Wiley; 1981:212-236.
23. Edelman RR, Salanitri G, Brand R, et al. Magnetic resonance imaging of the pancreas at 3.0 tesla: qualitative and quantitative comparison with 1.5 tesla. Invest Radiol. 2006;41:175-180.
24. Uematsu H, Dougherty L, Takahashi M, et al. Abdominal imaging at 4 T MR system: a preliminary result. Eur J Radiol. 2003;47:161-163.
25. Deckers F, Corthouts B, Nackaerts Y, et al. The influence of MR field strength on the detection of focal liver lesions with superparamagnetic iron oxide. Eur Radiol. 1997;7:887-892.
26. Alger JR, Harreld JH, Chen S, et al. Time-to-echo optimization for spin echo magnetic resonance imaging of liver metastasis using superparamagnetic iron oxide particles. J Magn Reson Imaging. 2001;14:586-594.
27. Reimer P, Jahnke N, Fiebich M, et al. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide - enhanced MR imaging, and spiral CT-ROC analysis. Radiology. 2000;217:152-158.
28. Kuhl CK, Gieseke J, von Falkenhausen M, et al. Sensitivity encoding for diffusion-weighted MR imaging at 3.0 T: intraindividual comparative study. Radiology. 2005;234:517-526.
29. Pruessmann KP, Weiger M, Scheidegger MB, et al. SENSE: sensitivity encoding for fast MRI. Magn Reson Med. 1999;42:952-962.
30. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003; 13:1266-1276.
31. Jang HJ, Lim JH, Lee SJ, et al. Hepatocellular carcinoma: are combined CT during arterial portography and CT hepatic arteriography in addition to triple-phase helical CT all necessary for preoperative evaluation? Radiology. 2000;215:373-380.